{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:10:23Z","timestamp":1790133023143,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.revmed.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:59:23Z","timestamp":1537423163000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Le syndrome s\u00e9rotoninergique\u00a0: une revue actualis\u00e9e de la litt\u00e9rature"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-568X","authenticated-orcid":false,"given":"L.","family":"Jurek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nourredine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Megarbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"d\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-6859","authenticated-orcid":false,"given":"J.-M.","family":"Dorey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2018.08.010_bib0005","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.10.12.1076","article-title":"Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor","volume":"10","author":"Oates","year":"1960","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.revmed.2018.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"issue":"360","key":"10.1016\/j.revmed.2018.08.010_bib0015","first-page":"2086","article-title":"Syndrome s\u00e9rotoninergique\u00a0: mise au point et revue des cas annonc\u00e9s en Suisse","volume":"8","author":"Munz","year":"2012","journal-title":"Rev Med Suisse"},{"issue":"5","key":"10.1016\/j.revmed.2018.08.010_bib0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14740338.7.5.587","article-title":"Drug-induced serotonin syndrome: a review","volume":"7","author":"Sun-Edelstein","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"23","key":"10.1016\/j.revmed.2018.08.010_bib0025","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1056\/NEJM200506093522320","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0030","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1054\/mehy.2000.1047","article-title":"An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria","volume":"55","author":"Radomski","year":"2000","journal-title":"Med Hypotheses"},{"issue":"9","key":"10.1016\/j.revmed.2018.08.010_bib0040","first-page":"OE05","article-title":"Controversies in serotonin syndrome diagnosis and management: a review","volume":"11","author":"Uddin","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"10.1016\/j.revmed.2018.08.010_bib0045","first-page":"63","article-title":"Serotonin syndrome","volume":"40","author":"Thanacoody","year":"2012","journal-title":"Medecine"},{"issue":"1","key":"10.1016\/j.revmed.2018.08.010_bib0050","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1176\/appi.neuropsych.12040085","article-title":"Functional auditory hallucinations in a case of serotonin syndrome","volume":"25","author":"Ameen","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"9","key":"10.1016\/j.revmed.2018.08.010_bib0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.revmed.2018.08.010_bib0060","doi-asserted-by":"crossref","first-page":"g1626","DOI":"10.1136\/bmj.g1626","article-title":"Serotonin syndrome","volume":"348","author":"Buckley","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2018.08.010_bib0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12883-016-0616-1","article-title":"Conundrums in neurology: diagnosing serotonin syndrome\u2013a meta-analysis of cases","volume":"16","author":"Werneke","year":"2016","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neulet.2010.07.039","article-title":"Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome","volume":"482","author":"Shioda","year":"2010","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.revmed.2018.08.010_bib0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.revmed.2018.08.010_bib0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxrep.2017.12.001","article-title":"Clinical value of drugs of abuse point of care testing in an emergency department setting","volume":"5","author":"Lager","year":"2017","journal-title":"Toxicol Rep"},{"issue":"5","key":"10.1016\/j.revmed.2018.08.010_bib0085","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1360-0443.2006.01397.x","article-title":"Declared and undeclared substance use among emergency department patients: a population-based study","volume":"101","author":"Rockett","year":"2006","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1176\/appi.ajp.159.4.672-a","article-title":"Serotonin syndrome and atypical antipsychotics","volume":"159","author":"Duggal","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.revmed.2018.08.010_bib0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11940-016-0423-4","article-title":"Management of serotonin syndrome and neuroleptic malignant syndrome","volume":"18","author":"Katus","year":"2016","journal-title":"Curr Treat Options Neurol"},{"issue":"22","key":"10.1016\/j.revmed.2018.08.010_bib0100","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMra1407298","article-title":"Recognition and management of withdrawal delirium (Delirium Tremens)","volume":"371","author":"Schuckit","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2018.08.010_bib0105","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1177\/1060028014549184","article-title":"Dexmedetomidine in the treatment of serotonin syndrome","volume":"48","author":"Rushton","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"7\u20138","key":"10.1016\/j.revmed.2018.08.010_bib0110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1345\/aph.10203","article-title":"Serotonin syndrome: early management with cyproheptadine","volume":"35","author":"McDaniel","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0736-4679(98)00057-2","article-title":"Treatment of the serotonin syndrome with cyproheptadine","volume":"16","author":"Graudins","year":"1998","journal-title":"J Emerg Med"},{"issue":"5","key":"10.1016\/j.revmed.2018.08.010_bib0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S1481803500012653","article-title":"Dantrolene for the treatment of MDMA toxicity","volume":"12","author":"Grunau","year":"2010","journal-title":"CJEM"},{"issue":"5","key":"10.1016\/j.revmed.2018.08.010_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S1481803500012598","article-title":"Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review","volume":"12","author":"Grunau","year":"2010","journal-title":"CJEM"},{"issue":"448","key":"10.1016\/j.revmed.2018.08.010_bib0130","first-page":"871","article-title":"Antidepressants and the serotonin syndrome in general practice","volume":"49","author":"Mackay","year":"1999","journal-title":"Br J Gen Pract"},{"issue":"8","key":"10.1016\/j.revmed.2018.08.010_bib0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/00048670701449237","article-title":"Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: Hierarchy of risk","volume":"41","author":"Silins","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J Affect Disord"},{"issue":"2","key":"10.1016\/j.revmed.2018.08.010_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vascn.2014.07.003","article-title":"Role of 5-HT1A- and 5-HT2A receptors for the murine model of the serotonin syndrome","volume":"70","author":"Haberzettl","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"10.1016\/j.revmed.2018.08.010_bib0150","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450\u00a0polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci Med Pathol"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.neuropharm.2011.01.025","article-title":"Implication of 5-HT2B receptors in the serotonin syndrome","volume":"61","author":"Diaz","year":"2011","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.revmed.2018.08.010_bib0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.revmed.2018.08.010_bib0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the drug transporter gene ABCB1\u00a0predict antidepressant treatment response in depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0170","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajmg.b.32309","article-title":"ABCB1\u00a0gene variants and antidepressant treatment outcome: a meta-analysis","volume":"168","author":"Breitenstein","year":"2015","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/026988110201600420","article-title":"Possible serotonin syndrome after combination of buspirone and St John's Wort","volume":"16","author":"Dannawi","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.revmed.2018.08.010_bib0180","doi-asserted-by":"crossref","first-page":"w14043","DOI":"10.4414\/smw.2015.14043","article-title":"Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling","volume":"145","author":"Liechti","year":"2015","journal-title":"Swiss Med Wkly"},{"issue":"PtA","key":"10.1016\/j.revmed.2018.08.010_bib0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2017.07.026","article-title":"Pharmacological profile of mephedrone analogs and related new psychoactive substances","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.revmed.2018.08.010_bib0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JCP.0000000000000344","article-title":"Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database","volume":"35","author":"Abadie","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.revmed.2018.08.010_bib0195","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.therap.2017.03.004","article-title":"Effets ind\u00e9sirables \u00ab\u00a0graves\u00a0\u00bb du tramadol\u00a0: bilan 2011\u20132015\u00a0de pharmacovigilance en France","volume":"72","author":"Moulis","year":"2017","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.revmed.2018.08.010_bib0205","first-page":"283","article-title":"Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation","volume":"10","author":"Nakayama","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.revmed.2018.08.010_bib0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpsyt.2017.00152","article-title":"Novel psychoactive substances\u2014Recent progress on neuropharmacological mechanisms of action for selected drugs","volume":"8","author":"Hassan","year":"2017","journal-title":"Front Psychiatry"},{"issue":"6","key":"10.1016\/j.revmed.2018.08.010_bib0215","article-title":"Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents","volume":"19","author":"Nguyen","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"issue":"6","key":"10.1016\/j.revmed.2018.08.010_bib0220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.therap.2016.05.005","article-title":"Les aspects actuels de l\u2019usage de l\u2019ecstasy\/MDMA en France","volume":"71","author":"Spadari","year":"2016","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.revmed.2018.08.010_bib0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharma.2011.11.006","article-title":"Pour que l\u2019\u00e9ducation th\u00e9rapeutique du patient devienne pour le pharmacien une posture de travail","volume":"70","author":"Allenet","year":"2012","journal-title":"Ann Pharm Fr"},{"issue":"12","key":"10.1016\/j.revmed.2018.08.010_bib0230","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.lpm.2009.05.020","article-title":"Une politique pour l\u2019\u00e9ducation th\u00e9rapeutique du patient","volume":"38","author":"Bourdillon","year":"2009","journal-title":"Presse Med"},{"issue":"5","key":"10.1016\/j.revmed.2018.08.010_bib0235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.neuropharm.2007.07.009","article-title":"Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice","volume":"53","author":"Fox","year":"2007","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.revmed.2018.08.010_bib0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.mp.4001926","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients","volume":"12","author":"Serretti","year":"2007","journal-title":"Mol Psychiatry"},{"issue":"7","key":"10.1016\/j.revmed.2018.08.010_bib0245","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archpsyc.64.7.783","article-title":"Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression","volume":"64","author":"Hu","year":"2007","journal-title":"Arch Gen Psychiatry"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318306994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318306994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:26Z","timestamp":1759336826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318306994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0248866318306994"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.08.010","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le syndrome s\u00e9rotoninergique\u00a0: une revue actualis\u00e9e de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}